Related Experiment Video
Updated: Oct 12, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Molecular tests for prediction of tumor sensitivity to cytotoxic drugs
Evgeny N Imyanitov1, Aglaya G Iyevleva2
1Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, St.-Petersburg, 197758, Russia; Department of Medical Genetics, St.-Petersburg Pediatric Medical University, St.-Petersburg, 194100, Russia; Department of Oncology, I.I. Mechnikov North-Western Medical University, St.-Petersburg, 191015, Russia.
Abstract:
Chemotherapy constitutes the backbone of cancer treatment. Several predictive assays assist personalized administration of cytotoxic drugs and are recommended for use in a clinical setting. The deficiency of DNA repair by homologous recombination (HRD), which is caused by inactivation of BRCA1/2 genes or other genetic events, is associated with high tumor responsiveness to platinum compounds, bifunctional alkylating agents and topoisomerase II poisons. Low activity of MGMT predicts the efficacy of nitrosoureas and tetrazines. Some clinically established pharmacogenetic tests allow for the adjustment of drug dosage, for example, the analysis of DPYD allelic variants for administration of fluoropyrimidines and UGT1A1 genotyping for the use of irinotecan. While there are promising molecular predictors of tumor sensitivity to pemetrexed, gemcitabine and taxanes, they remain in the investigational stage and require additional validation. Comprehensive molecular analysis of tumors obtained from drug responders and non-responders is likely to reveal new clinically useful predictive markers for cytotoxic therapy.
Insights
Predictive assays guide chemotherapy by identifying tumor sensitivity to specific drugs. Analyzing DNA repair and gene variants helps personalize cancer treatment for better outcomes.
Area of Science:
- Oncology
- Pharmacogenomics
- Molecular Diagnostics
Background:
- Chemotherapy is a cornerstone of cancer treatment, necessitating personalized approaches.
- Predictive molecular assays are crucial for optimizing cytotoxic drug administration in clinical settings.
- Tumor genetic profiles significantly influence response to various chemotherapeutic agents.
Purpose of the Study:
- To review established and emerging molecular predictors for chemotherapy response.
- To highlight the clinical utility of assays assessing DNA repair and drug metabolism.
- To underscore the potential of comprehensive molecular profiling for discovering novel predictive markers.
Main Methods:
- Review of existing literature on predictive assays for chemotherapy.
- Analysis of established pharmacogenetic tests (e.g., DPYD, UGT1A1).
- Discussion of molecular markers associated with drug sensitivity (e.g., HRD, MGMT).
Main Results:
- Homologous recombination deficiency (HRD) predicts response to platinum compounds and other agents.
- Low MGMT activity indicates sensitivity to nitrosoureas and tetrazines.
- Established pharmacogenetic tests guide dosing for fluoropyrimidines and irinotecan.
Conclusions:
- Molecular assays are vital for personalized chemotherapy, guiding drug selection and dosage.
- While some predictors are clinically validated, others require further investigation.
- Future research focusing on comprehensive molecular analysis will likely uncover new predictive markers for cytotoxic therapies.
